298 related articles for article (PubMed ID: 15475440)
1. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
[TBL] [Abstract][Full Text] [Related]
2. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
Madhusudan S; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Ganesan TS
J Clin Oncol; 2005 Sep; 23(25):5950-9. PubMed ID: 16135466
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
Jatoi A; Dakhil SR; Nguyen PL; Sloan JA; Kugler JW; Rowland KM; Soori GS; Wender DB; Fitch TR; Novotny PJ; Loprinzi CL
Cancer; 2007 Sep; 110(6):1396-403. PubMed ID: 17674351
[TBL] [Abstract][Full Text] [Related]
4. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Jan; 21(1):75-87; discussion 1-2. PubMed ID: 10090426
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Tsimberidou AM; Thomas D; O'Brien S; Andreeff M; Kurzrock R; Keating M; Albitar M; Kantarjian H; Giles F
Cancer Chemother Pharmacol; 2002 Sep; 50(3):237-42. PubMed ID: 12203106
[TBL] [Abstract][Full Text] [Related]
6. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
7. The effect of etanercept on Graves' ophthalmopathy: a pilot study.
Paridaens D; van den Bosch WA; van der Loos TL; Krenning EP; van Hagen PM
Eye (Lond); 2005 Dec; 19(12):1286-9. PubMed ID: 15550932
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
9. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
Wallenius M; Rødevand E; Skomsvoll JF
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
13. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
14. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.
Matteson EL; Choi HK; Poe DS; Wise C; Lowe VJ; McDonald TJ; Rahman MU
Arthritis Rheum; 2005 Jun; 53(3):337-42. PubMed ID: 15934127
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
16. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.
Monk JP; Phillips G; Waite R; Kuhn J; Schaaf LJ; Otterson GA; Guttridge D; Rhoades C; Shah M; Criswell T; Caligiuri MA; Villalona-Calero MA
J Clin Oncol; 2006 Apr; 24(12):1852-9. PubMed ID: 16622259
[TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
18. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
Tsimberidou AM; Giles FJ; Duvic M; Kurzrock R
J Am Acad Dermatol; 2004 Aug; 51(2):200-4. PubMed ID: 15280837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]